The first clinical application of this novel technology was explored as a potential therapy for HIV infection, in which cytotoxic CD8+ T lymphocytes (CTLs) were genetically modified to express CD4—the natural ligand of HIV—as an extracellular domain, linked to a transmembrane region and an intracellular CD3ζ signaling domain [14]. Here, CD4 is linked to HIV infectious disease.